CA224（Cat No.:I005372）is a potent, selective inhibitor of the receptor tyrosine kinase EphA2, which plays a critical role in tumor progression, angiogenesis, and metastasis. It has shown promise in preclinical studies for targeting various cancers, particularly those resistant to traditional therapies. By blocking EphA2 signaling, CA224 can inhibit tumor growth, reduce angiogenesis, and prevent cancer cell migration. With its targeted mechanism of action, CA224 offers a potential therapeutic approach for cancers such as breast, lung, and ovarian, where EphA2 is often overexpressed, providing new hope for personalized cancer treatment.